Hot Features
Registrieren Sie sich für Echtzeit-Charts, Analysetools und Preise.
OSAKA, Japan, and CAMBRIDGE, Mass., May 14 /PRNewswire/ -- Takeda Pharmaceutical Company Limited ("Takeda", TSE: 4502) and Millennium Pharmaceuticals, Inc. ("Millennium", Nasdaq: MLNM) today...
OSAKA, Japan, and CAMBRIDGE, Mass., May 14 /PRNewswire-FirstCall/ -- Takeda Pharmaceutical Company Limited ("Takeda"), (TSE:4502) and Millennium Pharmaceuticals, Inc. ("Millennium...
OSAKA, Japan, and CAMBRIDGE, Mass., May 9 /PRNewswire-FirstCall/ -- Takeda Pharmaceutical Company Limited, "Takeda", (TSE:4502) and Millennium Pharmaceuticals, Inc., "Millennium" (NASDAQ:MLNM...
NEW YORK, May 6 /PRNewswire/ -- Mergent, Inc., administrator for the Healthshares(TM) Indexes, a series of 20 underlying indexes for the HealthShares(TM) Exchange Traded Funds, today announced...
NEW YORK, May 5 /PRNewswire/ -- Standard & Poor's will make the following changes to the S&P MidCap 400 and S&P SmallCap 600: -- DreamWorks Animation SKG Inc. (NYSE:DWA) will replace...
OSAKA, Japan, and CAMBRIDGE, Mass., April 29 /PRNewswire-FirstCall/ -- Takeda Pharmaceutical Company Limited ("Takeda", TSE: 4502) and Millennium Pharmaceuticals, Inc. (NASDAQ:MLNM) today...
OSAKA, Japan and NEW YORK, April 11 /PRNewswire-FirstCall/ -- Takeda Pharmaceutical Company Limited ("Takeda", TSE: 4502) today announced the commencement of its cash tender offer for all...
- Strong U.S. sales growth to $83.5 million, up 13 percent over fourth-quarter 2007 and 42 percent over first-quarter 2007 - CAMBRIDGE, Mass., April 10 /PRNewswire-FirstCall/ -- Millennium...
- Acquisition Accelerates Takeda's Vision of Becoming a Global Leader in Oncology - OSAKA, Japan, and CAMBRIDGE, Mass., April 10 /PRNewswire-FirstCall/ -- Takeda Pharmaceutical Company Limited...
- Company advances oral antagonist of CCR9, a chemokine receptor believed to play a critical role in Crohn's disease - CAMBRIDGE, Mass., March 17 /PRNewswire-FirstCall/ -- Millennium...
| Zeitraum † | Änderung | Änderung % | Handelsbeginn | Hoch | Niedrig | Durchsch. Volumen | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| 12 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| 26 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| 52 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| 156 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| 260 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| Keine Diskussionen Gefunden. |
| Neuen Thread Erstellen |
Support: +44 (0) 203 8794 460 | support@advfn.de
Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen
Premium
